Salesforce Reiterates FY30 $63B Target After Strong Q2, But Organic Acceleration Proof Still Missing

What happened

Salesforce announced a fiscal 2030 revenue target of over $63 billion, echoing a goal first outlined in February 2026, following a second-quarter report that showed higher profit and revenue driven by accelerating demand for AI and data products. While the news is encouraging, it lacks specific details on current remaining performance obligation growth or organic subscription acceleration—the metrics critical to assessing whether AI monetization is offsetting potential seat compression. The DeepValue master report had maintained a WAIT rating pending evidence that cRPO holds near 14% and subscription growth re-accelerates organically. This announcement, though positive in tone, does not by itself resolve that uncertainty. Investors should treat the news as a sign of management confidence but still require quantitative confirmation from the next earnings release.

Implication

Over the long term, the reaffirmation of the $63 billion target suggests management remains confident in AI-led growth, yet the exact path hinges on whether data readiness and Agentforce adoption translate into sustainable organic revenue. If the upcoming earnings release shows cRPO growth at or above 14% and subscription revenue accelerating without acquisition aid, the bear case would weaken and the stock could re-rate toward the bull scenario of $195. Conversely, if cRPO falls below 12% or growth remains acquisition-dependent, the stock may drift toward the bear scenario of $145. Additionally, investors must monitor seat compression risks and pricing complexity, which could undermine the value of long-term targets. Thus, while the narrative is improving, the WAIT rating remains appropriate until the critical growth-quality metrics are confirmed.

Thesis delta

The thesis previously called for a WAIT until proof of organic acceleration. This news provides preliminary evidence of AI demand strength, but it does not include the specific cRPO and subscription growth figures that would confirm the bull case. Therefore, the core thesis is unchanged, with a slightly positive tilt, pending the detailed second-quarter numbers.